## Abstract ## BACKGROUND. Myelodysplastic syndromes (MDS) became reportable to the Surveillance, Epidemiology, and End Results (SEER) Program (the United States cancer surveillance program) in 2001. This provided the first opportunity to examine the incidence and survival of patients with MDS in
Validation of survival-predictive models in myelodysplastic syndromes
✍ Scribed by Miguel A. Sanz; J. Ignacio Lorenzo; Guillermo F. Sanz; Sonia Garcia; Victoria Amigó; Teresa Vallespí; Marta Torrabadella; Ma Consuelo Cañizo; Jesús San Miguel
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 103 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The problem of assessing the validity and value of prognostic survival models presented in the literature for a particular population for which some data has been collected is discussed. Methods are sketched to perform validation through 'calibration', that is by embedding the literature model in a
## Abstract The prognostic significance of the peripheral blood absolute lymphocyte count (ALC) has been carefully examined in lymphoid malignancies, but the importance of the baseline ALC in chronic myeloid neoplasms is less clear. In a recent analysis of myelodysplastic syndromes (MDS) associated